10/007,621

```
FILE 'HOME' ENTERED AT 10:29:18 ON 06 JUN 2005

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'BIOSIS' ENTERED AT 10:30:00 ON 06 JUN 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 10:30:00 ON 06 JUN 2005

FILE 'CAPLUS' ENTERED AT 10:30:00 ON 06 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:30:00 ON 06 JUN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 10:30:00 ON 06 JUN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s modified nucleotide?
L1         9076 MODIFIED NUCLEOTIDE?

=> s l1 and link? (6a) aminophenol
L2            0 L1 AND LINK? (6A) AMINOPHENOL

=> s l1 and aminophenol
L3           16 L1 AND AMINOPHENOL

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4            16 DUP REM L3 (0 DUPLICATES REMOVED)

=> d l4 bib abs 1-16

L4   ANSWER 1 OF 16  USPATFULL on STN
AN     2005:138619  USPATFULL
TI     Heterocyclic compounds and methods of making and using thereof
IN     Rao, Yeleswarapu Koteswar, Hyderabad, INDIA
       Pal, Manojit, Hyderabad, INDIA
       Sharma, Vedula Manohar, Hyderabad, INDIA
       Venkateswarlu, Akella, Hyderabad, INDIA
       Pillarisetti, Ram, Norcross, GA, UNITED STATES
PI     US 2005119269      A1   20050602
AI     US 2004-976284     A1   20041028 (10)
PRAI   IN 2003-8612003     20031028
       US 2004-610163P     20040915 (60)
DT     Utility
FS     APPLICATION
LREP   WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA,
       30357-0037, US
CLMN   Number of Claims: 59
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 13564
AB     Compounds of formula (I), and methods and/or compositions comprising
       compounds that are effective in modulating inflammatory responses, such
       as those resulting from AGE and glycated protein accumulation are
       provided. Methods and/or compositions comprising compounds that are
       effective in modulating smooth muscle cell proliferation and the
       diseases or conditions related thereto are also provided.    ##STR1##
```

L4 ANSWER 2 OF 16 USPATFULL on STN
AN 2005:131877 USPATFULL
TI Medical devices employing triazine compounds and compositions thereof
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Hyderabad, IN, UNITED STATES
Pal, Manojit, Hyderabad, INDIA
Reddy, Jangalgar Tirupathy, Hyderabad, INDIA
Murali Krishna Reddy, Velagala Venkata Rama, Hyderabad, INDIA
Sridevi, Bhatlapenumarthy Sesha, Hyderabad, INDIA
Kumar, Potlapally Rajender, Hyderabad, INDIA
Reddy, Gaddam Om, Hyderabad, INDIA
PI US 2005113341 A1 20050526
AI US 2004-951305 A1 20040927 (10)
RLI Division of Ser. No. US 2003-400134, filed on 26 Mar 2003, PENDING Continuation-in-part of Ser. No. US 2003-390485, filed on 17 Mar 2003, PENDING Continuation of Ser. No. US 2002-253388, filed on 23 Sep 2002, ABANDONED
PRAI US 2001-324147P 20010921 (60)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 10723
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

L4 ANSWER 3 OF 16 USPATFULL on STN
AN 2004:335614 USPATFULL
TI Stabilized polynucleotides for use in RNA interference
IN Leake, Devin, Denver, CO, UNITED STATES
Reynolds, Angela, Denver, CO, UNITED STATES
Khvorova, Anastasia, Denver, CO, UNITED STATES
Marshall, William, Denver, CO, UNITED STATES
PI US 2004266707 A1 20041230
AI US 2003-613077 A1 20030701 (10)
RLI Continuation-in-part of Ser. No. US 2003-406908, filed on 2 Apr 2003, PENDING
DT Utility
FS APPLICATION
LREP KALOW & SPRINGUT LLP, 488 MADISON AVENUE, 19TH FLOOR, NEW YORK, NY, 10022
CLMN Number of Claims: 88
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 4224
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for performing RNA interference comprising a wide variety of stabilized polynucleotides suitable for use in serum-containing media and for in vivo applications, such as therapeutic applications, are provided. These polynucleotides permit effective and efficient applications of RNA interference to applications such as

diagnostics and therapeutics through the use of one or more modifications including orthoesters, terminal conjugates, modified linkages and 2'**modified nucleotides**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 16 USPATFULL on STN
AN 2004:307045 USPATFULL
TI Terminal-phosphate-labeled nucleotides with new linkers
IN Kumar, Shiv, Belle Mead, NJ, UNITED STATES
McDougall, Mark, Arroyo Grande, CA, UNITED STATES
Sood, Anup, Flemington, NJ, UNITED STATES
Nelson, John, Hillsborough, NJ, UNITED STATES
Fuller, Carl, Berkeley Heights, NJ, UNITED STATES
Macklin, John, Wenonah, NJ, UNITED STATES
Mitsis, Paul, Trenton, NJ, UNITED STATES
PI US 2004241716 A1 20041202
AI US 2004-772996 A1 20040205 (10)
PRAI US 2003-445189P 20030205 (60)
DT Utility
FS APPLICATION
LREP Amersham Biosciences Corp, 800 Centennial Avenue, Piscataway, NJ, 08855
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 2522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes methods of using terminal-phosphate-labeled nucleotides in the presence of a manganese salt to enhance their substrate properties towards various enzymes. Particularly described are methods of detecting a nucleic acid in a sample, based on the use of terminal-phosphate-labeled nucleotides as substrates for nucleic acid polymerases, in the presence of a manganese salt. Further provided are manganese complexes of terminal-phosphate-labeled nucleotides as well as terminal-phosphate-labeled nucleotides with new linkers with enhanced substrate properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 16 USPATFULL on STN
AN 2004:286782 USPATFULL
TI Methods and compositions of novel triazine compounds
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
Pal, Manojit, Hyderabad, INDIA
Reddy, Jangalgar Tirupathy, Hyderabad, INDIA
Reddy, Velagala Venkira Rama Murali Krishna, Hyderabad, INDIA
Sridevi, Bhatlapenumarphy Shesha, Hyderabad, INDIA
Kumar, Potlapally Rajender, Hyderabad, INDIA
Reddy, Gaddam Om, Hyderabad, INDIA
PI US 2004224950 A1 20041111
AI US 2003-400140 A1 20030326 (10)
RLI Continuation-in-part of Ser. No. US 2003-390485, filed on 17 Mar 2003, PENDING Continuation of Ser. No. US 2002-253388, filed on 23 Sep 2002, ABANDONED
PRAI US 2001-324147P 20010921 (60)
DT Utility
FS APPLICATION
LREP JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, ATLANTA, GA, 30309
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 11181
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 16 USPATFULL on STN
AN 2004:286243 USPATFULL
TI siRNA induced systemic gene silencing in mammalian systems
IN Leake, Devin, Denver, CO, UNITED STATES
Reynolds, Angela, Conifer, CO, UNITED STATES
Khvorova, Anastasia, Boulder, CO, UNITED STATES
Marshall, William, Boulder, CO, UNITED STATES
PA Dharmacon Inc., Lafayette, CO, 80026 (U.S. corporation)
PI US 2004224405 A1 20041111
AI US 2003-431027 A1 20030506 (10)
DT Utility
FS APPLICATION
LREP KALOW & SPRINGUT LLP, 488 MADISON AVENUE, 19TH FLOOR, NEW YORK, NY, 10022
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2637
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to methods and compositions for performing gene silencing in mammalian cells by targeting a region of a non-protein coding target nucleic acid sequence with at least one siRNA molecule comprising a duplex region of between 19 and 30 base pairs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 16 USPATFULL on STN
AN 2004:268339 USPATFULL
TI Methods and compositions of novel triazine compounds
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
Pal, Manojit, Hyderabad, INDIA
Reddy, Jangalgar Tirupathy, Hyderabad, INDIA
Krishma Reddy, Velagala Venkata Rama Murali, Hyderabad, INDIA
Sesila Sridevi, Bhatlapenumarthy, Hyderabad, INDIA
Kumar, Potlapally Rajender, Hyderabad, INDIA
Reddy, Gaddam Om, Hyderabad, INDIA
PI US 2004209882 A1 20041021
AI US 2003-400169 A1 20030326 (10)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 12036
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed

to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 16 USPATFULL on STN
AN 2004:268338 USPATFULL
TI Methods and compositions of novel triazine compounds
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Hydrabad, INDIA
Pal, Manojit, Hydrabad, INDIA
Reddy, Jangalgar Tirupathy, Hydrabad, INDIA
Krishna Reddy, Velagala Venkata Rama Murali, Hydrabad, INDIA
Sridevi, Bhatlapenumarthy Sesha, Hydrabad, INDIA
Kumar, Potlapally Rajender, Hyderbad, INDIA
Reddy, Gaddam Om, Hydrabad, INDIA
PI US 2004209881 A1 20041021
AI US 2003-400134 A1 20030326 (10)
DT Utility
FS APPLICATION
LREP JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, ATLANTA, GA, 30309
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 9019
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 16 USPATFULL on STN
AN 2004:268337 USPATFULL
TI Methods and compositions of novel triazine compounds
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Begumpet, INDIA
Pal, Manojit, Miyapur, INDIA
Reddy, Jangalgar Tirupathy, Miyapur, INDIA
Krlshna Reddy, Velagala Venkata Rama Murali, Kukatpally, INDIA
Sridevi, Bhatlapenumarthy Sesha, Gandhinagar, INDIA
Kumar, Potlapally Rajender, Miyapur, INDIA
Reddy, Gaddam Om, Miyapur, INDIA
PI US 2004209880 A1 20041021
AI US 2003-397968 A1 20030326 (10)
DT Utility
FS APPLICATION

LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 10190
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 16 USPATFULL on STN
AN 2004:255110 USPATFULL
TI Stabilized polynucleotides for use in RNA interference
IN Leake, Devin, Denver, CO, UNITED STATES
Reynolds, Angela, Conifer, CO, UNITED STATES
Khvorova, Anastasia, Boulder, CO, UNITED STATES
Marshall, William, Boulder, CO, UNITED STATES
Scaringe, Stephen, Lafayette, CO, UNITED STATES
PA Dharmacon, Inc., Lafayette, CO, UNITED STATES, 80026 (U.S. corporation)
PI US 2004198640 A1 20041007
AI US 2003-406908 A1 20030402 (10)
DT Utility
FS APPLICATION
LREP KALOW & SPRINGUT LLP, 488 MADISON AVENUE, 19TH FLOOR, NEW YORK, NY, 10022
CLMN Number of Claims: 69
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 2440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for performing RNA interference comprising a wide variety of stabilized polynucleotides suitable for use in serum-containing media and for in vivo applications, such as therapeutic applications, are provided. These polynucleotides permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of one or more modifications including orthoesters, terminal conjugates, modified linkages and 2'**modified nucleotides**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 16 USPATFULL on STN
AN 2004:101778 USPATFULL
TI Methods and compositions of novel triazine compounds
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Campbell, Karen A., Durham, NC, UNITED STATES
PI US 2004077648 A1 20040422
AI US 2003-390485 A1 20030317 (10)
RLI Continuation of Ser. No. US 2002-253388, filed on 23 Sep 2002, ABANDONED
PRAI US 2001-324147P 20010921 (60)
DT Utility
FS APPLICATION
LREP JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, SUITE 2800, ATLANTA, GA, 30309

CLMN Number of Claims: 75
ECL Exemplary Claim: 1
DRWN 54 Drawing Page(s)
LN.CNT 10058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 16 USPATFULL on STN
AN 2004:64489 USPATFULL
TI Templated molecules and methods for using such molecules
IN Pedersen, Henrik, Bagsvaerd, DENMARK
Gouilaev, Alex Haahr, Vesko Sjaelland, DENMARK
Franch, Thomas, Odense C, DENMARK
Sams, Christian Klarner, Frederiksberg C, DENMARK
Olsen, Eva Kampmann, Herlev, DENMARK
Slok, Frank Abilgaard, Kobenhavn N, DENMARK
Husemoen, Gitte Nystrup, Kobenhavn N, DENMARK
Felding, Jakob, Charlottenlund, DENMARK
Hyldtoft, Lene, Virum, DENMARK
Norregaard-Madsen, Mads, Birkerod, DENMARK
Godskesen, Michael Anders, Vedbaek, DENMARK
Glad, Sanne Schroder, Ballerup, DENMARK
Thisted, Thomas, Frederikssund, DENMARK
Freskgard, Per-Ola, Vellinge, SWEDEN
Holtmann, Anette, Ballerup, DENMARK
PA Nuevolution A/S, Copenhagen, DENMARK (non-U.S. corporation)
PI US 2004049008 A1 20040311
AI US 2002-175539 A1 20020620 (10)
PRAI DK 2001-962 20010620
US 2001-299443P 20010621 (60)
US 2002-364056P 20020315 (60)
DT Utility
FS APPLICATION
LREP BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303
CLMN Number of Claims: 316
ECL Exemplary Claim: 1
DRWN 100 Drawing Page(s)
LN.CNT 11215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for synthesising templated molecules. In one aspect of the invention, the templated molecules are linked to the template which templated the synthesis thereof. The intion allows the generation of libraries which can be screened for e.g. therapeutic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 16 USPATFULL on STN
AN 2003:194996 USPATFULL
TI Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
IN Hardin, Susan H., Bellaire, TX, UNITED STATES
Gao, Xiaolian, Houston, TX, UNITED STATES
Briggs, James, Katy, TX, UNITED STATES
Willson, Richard, Houston, TX, UNITED STATES

Tu, Shiao-Chun, Houston, TX, UNITED STATES
PI US 2003134807 A1 20030717
AI US 2001-7621 A1 20011203 (10)
PRAI US 2000-250764P 20001201 (60)
DT Utility
FS APPLICATION
LREP ROBERT W STROZIER, PLLC, 2925 BRIARPARK, SUITE 930, HOUSTON, TX, 77042
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 3557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleotide triphosphate probes containing a molecular and/or atomic tag on a a γ and/or β phosphate group and/or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 16 USPATFULL on STN
AN 2002:129802 USPATFULL
TI Xanthene dyes and their application as luminescence quenching compounds
IN Haugland, Richard P., Eugene, OR, United States
Singer, Victoria L., Eugene, OR, United States
Yue, Stephen T., Eugene, OR, United States
PA Molecular Probes, Inc., Eugene, OR, United States (U.S. corporation)
PI US 6399392 B1 20020604
AI US 2000-556464 20000421 (9)
PRAI US 1999-130808P 19990423 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ceperley, Mary E.
LREP Helfenstein, Allegra, Skaugset, Anton, Stracker, Elaine
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 2459
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The quenching compounds of the invention are nitrogen-substituted xanthenes that are substituted by one or more aromatic or heteroaromatic quenching moieties. The quenching compounds of the invention exhibit little or no observable fluorescence and efficiently quench a broad spectrum of luminescent compounds. The chemically reactive quenching compounds possess utility for labeling a wide variety of substances, including biomolecules. These labeled substances are highly useful for a variety of energy-transfer assays and applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 16 USPATFULL on STN
AN 2002:129750 USPATFULL
TI γ-phosphoester nucleoside triphosphates
IN Kao, C. Cheng, Bloomington, IN, United States
Widlanski, Theodore, Bloomington, IN, United States
Vassiliou, William, Bloomington, IN, United States
Epp, Jeffrey, Indianapolis, IN, United States
PA Advanced Research and Technology Institute, Inc., Indianapolis, IN, United States (U.S. corporation)
PI US 6399335 B1 20020604
AI US 1999-441108 19991116 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Riley, Jezia
LREP Osman, Richard Aron
CLMN Number of Claims: 23
ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and compositions for polymerizing a particular nucleotide with a polymerase. In general, the method involves (a) forming a mixture of a polymerase and a nucleoside triphosphate (NTP) comprising α, β and γ phosphates and a γ-phosphate phosphoester-linked functional group; and incubating the mixture under conditions wherein the polymerase catalyzes cleavage of the NTP between the α and β phosphates, liberating a pyrophosphate comprising the functional group and polymerizing the resultant nucleoside monophosphate, i.e. incorporates the nucleoside monophosphate in a nascent polynucleotide. A variety of functional groups compatible with the polymerization reaction are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 16 USPATFULL on STN
AN 96:87702 USPATFULL
TI Unsymmetrical complexing agents and targeting immunoreagents useful in thearpeutic and diagnostic compositions and methods
IN Delecki, Daniel J., Upper Merion Township, Montgomery County, PA, United States
Saha, Ashis K., Frazer, PA, United States
Snow, Robert A., West Chester, PA, United States
PA Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)
PI US 5559214 19960924
AI US 1993-69242 19930528 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Wu, Shean C.; Assistant Examiner: Chapman, Lara E.
LREP Fish & Richardson PC
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3248
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 18 bib abs 1-3

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:793841 CAPLUS
DN 137:307013
TI Non-enzymatic liposome-linked closely spaced array electrodes assay (NEL-ELA) for detecting and quantifying nucleic acids
IN Bredehorst, Reinhard; Hintsche, Rainer; Heuberger, Anton
PA Fraunhofer-Gesellschaft zur Foerderung der Angewandten Forschung e.V., Germany
SO PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002081739	A2	20021017	WO 2002-EP3892	20020408
WO 2002081739	A3	20040129		
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1409728	A2	20040421	EP 2002-735236	20020408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
PRAI US 2001-282164P	P	20010409		
WO 2002-EP3892	W	20020408		

AB The invention concerns target nucleic acids or amplicons thereof bound to immobilized capture oligonucleotides by mol. biol. reactions, are detected and quantified with affinity liposomes containing encapsulated electrochem. detectable reporter mols. susceptible to redox recycling and surface-attached affinity components capable of specifically binding to captured target nucleic acids or amplicons thereof in a structure restricted manner. Specifically bound affinity liposomes are lysed by temperature- or detergent-mediated mechanisms and released reporter mols. are quantitated via redox recycling using voltammetry in conjunction with a closely spaced array of thin film nobel metal electrodes. The quantity of released reporter mols. is a proportional measure of the quantity of target nucleic acids in the sample. For amplified assay procedures polymeric carrier mols. capable of binding multiple affinity liposomes or preformed complexes of affinity liposomes are utilized.

L8 ANSWER 2 OF 3 USPATFULL on STN
AN 88:50246 USPATFULL
TI Compositions and methods for functionalizing nucleic acids
IN Snitman, David L., Boulder, CO, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 4762779 19880809
AI US 1985-744508 19850613 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Marantz, Sidney; Assistant Examiner: Spiegel, Jack
LREP O'Toole, Marshall
CLMN Number of Claims: 4
ECL Exemplary Claim: 4
DRWN No Drawings
LN.CNT 411
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition and a method for 5'-labelling polynucleotides undergoing solid phase synthesis wherein a phosphoramidite of an ω-hydroxylamine is condensed to a support-bound polynucleotide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 3 USPATFULL on STN
AN 88:24488 USPATFULL
TI Method for derivitization of polynucleotides

IN Stabinsky, Yitzhak, Boulder, CO, United States
PA Amgen, Thousand Oaks, CA, United States (U.S. corporation)
PI US 4739044 19880419
AI US 1985-744798 19850613 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Brown, J. R.; Assistant Examiner: Rollins, John W.
LREP Marshall, O'Toole, Gerstein, Murray & Bicknell
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the preparation of a 3' end functionalized polynucleotide is disclosed. An amine-functionalized solid phase support is treated sequentially with an anhydride, then with an ω-hydroxylamine. A polynucleotide is chemically synthesized on the treated support and is subsequently cleaved therefrom by hydrolysis of the amide bonds. A polynucleotide having a 3' free primary amine is recovered for use in hybridization assays and other uses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

> d l10 bib abs 1-4

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:454920 CAPLUS
DN 139:32899
TI Electrochemical method for detecting water-borne pathogens
IN Fritsch, Ingrid; Beitle, Robert; Aguilar, Zoraida
PA USA
SO U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U. S. Ser. No. 978,734.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003108922	A1	20030612	US 2002-252342	20020923
	US 2002058279	A1	20020516	US 2001-978734	20011015
	US 6887714	B2	20050503		
PRAI	US 2000-240691P	P	20001016		
	US 2001-978734	A2	20011015		

AB A novel, surface immobilization electrochem. assay allows for rapid, accurate and highly sensitive detection of microorganisms and biol. mols. Known surface immobilization methods are utilized to bind an analyte to a surface. A binding material with a covalently attached electroactive complex generates elec. current in the presence of analyte. An electrode is used to detect the current, that is directly related to the concentration of analyte. The invention is especially suitable for detection of Cryptosporidium parvum. A sandwich-type immunoassay was performed in which a monoclonal IgM antibody to C. parvum was covalently attached via carboduimide coupling to 11-mercapto-1-undecanol and 11-mercapto-1-undecanoic acid self-assembled monolayers on gold macrochips, followed by capture of C. parvum oocysts from the sample solution, and attachment of a secondary antibody, labeled with alkaline phosphatase (AP). Bare gold macroelectrode and a microelectrode were used to detect p-aminophenol enzymically generated by the AP immobilized on the modified chip from a solution of 4 mM p-aminophenyl phosphate in 0.1 M Tris buffer (pH = 9). The detection limit for the microelectrode detection was 7 oocysts/L.

L10 ANSWER 2 OF 4 USPATFULL on STN
AN 2002:254481 USPATFULL
TI Dye intermediate and method
IN Griffiths, John, Leeds, UNITED KINGDOM
Mama, John, Leeds, UNITED KINGDOM
Millar, Valerie, Mid Glamorgan, UNITED KINGDOM
Briggs, Mark, Cardiff, UNITED KINGDOM
Hamilton, Alan, Amersham, UNITED KINGDOM
PA Nycomed Amersham plc, Amersham, UNITED KINGDOM (non-U.S. corporation)
PI US 6458966 B1 20021001
WO 9907793 19990218
AI US 2000-485177 20000424 (9)
WO 1998-GB2334 19980804
20000424 PCT 371 date
PRAI GB 1997-16476 19970804
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ceperley, Mary E.
LREP Romming, Jr., Royal N., Ryan, Stephen G.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Various classes of dyes are provided having acid, ester or amide groups for covalent linking to biomolecules. The dyes may be prepared by use of a compound of formula (I) ##STR1##

where R.sup.1 comprises a linker and a carboxy including acid, salt, ester including N-hydroxysuccinimide, activated ester or amide group;

R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H, C.sub.1-C.sub.10 alkyl or aralkyl or a group to modify solubility or electronic or spectral properties or a functional linking group: or R.sup.4-R.sup.5 and/or R.sup.2-R.sup.4 and/or R.sup.2-R.sup.3 are linked to form an extended ring system; and R.sup.6 is H or CHO or NO.

CAS INDEXING IS AVAILABLE FOR THIS PATENT..

L10 ANSWER 3 OF 4 USPATFULL on STN
AN 1999:167042 USPATFULL
TI Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production
IN Springer, Caroline Joy, Sutton, United Kingdom
Niculescu-Duvaz, Ion, Sutton, United Kingdom
PA Cancer Research Campaign Technology Limited, London, United Kingdom (non-U.S. corporation)
PI US 6005002 19991221
WO 9622277 19960725
AI US 1997-875099 19970716 (8)
WO 1996-GB112 19960119
19970716 PCT 371 date
19970716 PCT 102(e) date
PRAI GB 1995-1052 19950119
DT Utility
FS Granted
EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Davis, Brian J.
LREP Venable
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1249
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of formula (I) and (II) wherein X and Y are independently chlorine, bromine, iodine, a mesyl group CH.sub.3 SO.sub.3 or a tosyl group OSO.sub.2 phenyl (wherein phenyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from C.sub.1-4 alkyl, halogen, cyano or nitro; R.sup.1 and R.sup.2 are independently 1 to 4 optional substituents; Z.sup.1 and Z.sup.2 are each independently --O-- or --NH--; R.sup.3 is hydrogen, t-butyl or allyl; Z.sup.3 is a hydrocarbyl group such as carboxyethyl, optionally containing heteroatoms, and physiologically acceptable derivatives thereof. The compounds can be converted in situ into nitrogen mustard agents by the actions of enzymes such as carboxypeptidase or nitroreductase and are useful for the treatment of cancer. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:759132 CAPLUS
DN 124:146760
TI Oligonucleotide analogs containing unsaturated 3',5' and 2',5' allyl ether and allyl sulfide linkages capable of hybridizing to target nucleic acid sequences
IN Matteucci, Mark D.; Cao, Xiaodong
PA Gilead Sciences, Inc., USA
SO U.S., 77 pp. Cont.-in-part of U.S. Ser. No. 892,902.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5434257	A	19950718	US 1993-142785	19931026
	US 5817781	A	19981006	US 1992-892902	19920601
	AT 174599	E	19990115	AT 1993-915177	19930601
	WO 9511911	A1	19950504	WO 1994-US12202	19941025

W: CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

	US 6410702	B1	20020625	US 1998-165883	19981002
	US.2003120050	A1	20030626	US 2002-176763	20020621
	US 6683166	B2	20040127		
PRAI	US 1992-892902	A2	19920601		
	US 1993-142785	A	19931026		
	US 1998-165883	A1	19981002		

OS MARPAT 124:146760

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Oligonucleotide analogs I and II where X is S, O, CH2, CHF or CF2 ; X1 is O or S; R1 is independently H, an oligomer or a blocking group including PO3-2, O-dimethoxytrityl (DMTO), O-monomethoxytrityl (MMTO), H-phosphonate (OPO2H), methylphosphonate (OPO3CH3), methylphosphonamidite, or a phosphoramidite such as β-cyanoethylphosphoramidite; R2 independently is O-alkyl (C1-C12 including O-Me, O-Et, O-Pr, O-Bu and their isomers), S-alkyl(C1-C12), H, OH, OCH3, SCH3, OCH2CH:CH2 (O-allyl), OC3H7 (O-propyl), SCH2CHCH2, or a halogen (F, Cl, Br or I); B is independently a base, and n is 0-100, preferably 0-28; both R1 taken together can comprise a circular oligomer and may be covalently linked, for example, at a terminal 5' position with a terminal 2' or 3' position, are disclosed. The substitute linkage replace the usual phosphodiester linkage found in unmodified nucleic acids. The oligonucleotide analogs are easy to synthesize, stable in vivo, resistant to endogenous nucleases and are able to hybridize to target nucleic acid sequences in a sequence specific manner. Thus, e.g., 3'-H-phosphonate dimers III (X = O, S, preparation given) were incorporated into oligomers (5' TCT CTC TCT CT#T T#TT 3'; # = X-containing linkage) and tested for binding to single stranded DNA (3' AGA GAG AGA GAA AAA 5'): ΔTm was -3.25 and -3.0°, resp., for X = O and X = S.

```
=> d his

     (FILE 'HOME' ENTERED AT 10:29:18 ON 06 JUN 2005)

     FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:30:00 ON
     06 JUN 2005
L1          9076 S MODIFIED NUCLEOTIDE?
L2             0 S L1 AND LINK? (6A) AMINOPHENOL
L3            16 S L1 AND AMINOPHENOL
L4            16 DUP REM L3 (0 DUPLICATES REMOVED)
L5           164 S LINK? (15A) AMINOPHENOL
L6             7 S L5 AND NUCLEOTIDE?
L7             3 S L6 AND LINK? (15A) NUCLEOTIDE?
L8             3 DUP REM L7 (0 DUPLICATES REMOVED)
L9             4 S L6 NOT L8
L10            4 DUP REM L9 (0 DUPLICATES REMOVED)

=>
```

```
=> d his

     (FILE 'HOME' ENTERED AT 10:29:18 ON 06 JUN 2005)

     FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:30:00 ON
     06 JUN 2005
L1          9076 S MODIFIED NUCLEOTIDE?
L2             0 S L1 AND LINK? (6A) AMINOPHENOL
L3            16 S L1 AND AMINOPHENOL
L4            16 DUP REM L3 (0 DUPLICATES REMOVED)
L5           164 S LINK? (15A) AMINOPHENOL
L6             7 S L5 AND NUCLEOTIDE?
L7             3 S L6 AND LINK? (15A) NUCLEOTIDE?
L8             3 DUP REM L7 (0 DUPLICATES REMOVED)
L9             4 S L6 NOT L8
L10            4 DUP REM L9 (0 DUPLICATES REMOVED)

=> s l5 and fluorophore
L11            1 L5 AND FLUOROPHORE

=> d l11 bib abs

L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2001:222390  CAPLUS
DN   135:58012
TI   Density functional study of fluorescent indicators for the intracellular
     determination of Ca2+ and Mg2+
AU   Delabie, Annelies; Cielen, Els; Boens, Noel; Pierloot, Kristine
CS   Department of Chemistry, Quantum Chemistry Group, University of Leuven,
     Heverlee-Leuven, B-3001, Belg.
SO   Journal of the Chemical Society, Perkin Transactions 2 (2001), (4),
     468-475
     CODEN: JCSPGI; ISSN: 1472-779X
PB   Royal Society of Chemistry
DT   Journal
LA   English
AB   Fluorescent indicators for the intracellular determination of Ca2+ and Mg2+ have
     been studied by means of theor. calcns., based on D. Functional Theory
     (DFT). The indicators consist of the podant o-aminophenol
     -N,N,O-triacetic acid (APTRA), linked to an arylthiophene
     fluorophore, substituted in the para position with donor or
     acceptor groups. The interaction of Ca2+ and Mg2+ with the indicators was
     studied both in the gas phase and in solvent. In the gas phase, these
     cations both have a five-fold coordination. Binding with the cation
     results in a change in the hybridization state of the nitrogen from sp2 to
     sp3; the nitrogen lone pair is no longer part of the conjugated system.
     The metal-nitrogen interaction is given up in solvent; the structure
     relaxes so that the nitrogen lone pair can again participate in the
     conjugated system of the fluorophore. The effect of the
     electron-withdrawing or -donating substituents on the cation-indicator
     interaction was investigated. Two effects determine the nature of the
     complexation in solvent. Firstly, there is the inherent binding energy of
     the indicator with the metal, which is favored by electron-donating
     substituents and weakened by electron-withdrawing groups. Secondly, there
     is a stabilizing effect of the solvent on the free indicators; due to
     their smaller dipole moment, free indicators with electron-withdrawing
     groups are stabilized less by the solvent. For various substituents,
     these two effects evolve in opposite ways. This results in a small
     overall variation of complexation energies.
RE.CNT  17    THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
```

```
=> s modified nucleotide?
L1          9081 MODIFIED NUCLEOTIDE?

=> s l1 and aminonaphthol
L2             2 L1 AND AMINONAPHTHOL

=> d l2 bib abs 1-2

L2   ANSWER 1 OF 2  USPATFULL on STN
AN     2003:194996  USPATFULL
TI     Enzymatic nucleic acid synthesis: compositions and methods for altering
       monomer incorporation fidelity
IN     Hardin, Susan H., Bellaire, TX, UNITED STATES
       Gao, Xiaolian, Houston, TX, UNITED STATES
       Briggs, James, Katy, TX, UNITED STATES
       Willson, Richard, Houston, TX, UNITED STATES
       Tu, Shiao-Chun, Houston, TX, UNITED STATES
PI     US 2003134807       A1   20030717
AI     US 2001-7621        A1   20011203 (10)
PRAI   US 2000-250764P      20001201 (60)
DT     Utility
FS     APPLICATION
LREP   ROBERT W STROZIER, PLLC, 2925 BRIARPARK, SUITE 930, HOUSTON, TX, 77042
CLMN   Number of Claims: 20
ECL    Exemplary Claim: 1
DRWN   14 Drawing Page(s)
LN.CNT 3557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Nucleotide triphosphate probes containing a molecular and/or atomic tag
       on a a γ and/or β phosphate group and/or a base moiety having
       a detectable property are disclosed, and kits and method for using the
       tagged nucleotides in sequencing reactions and various assay. Also,
       phosphate and polyphosphate molecular fidelity altering agents are
       disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2   ANSWER 2 OF 2  USPATFULL on STN
AN     2002:129750  USPATFULL
TI     γ-phosphoester nucleoside triphosphates
IN     Kao, C. Cheng, Bloomington, IN, United States
       Widlanski, Theodore, Bloomington, IN, United States
       Vassiliou, William, Bloomington, IN, United States
       Epp, Jeffrey, Indianapolis, IN, United States
PA     Advanced Research and Technology Institute, Inc., Indianapolis, IN,
       United States (U.S. corporation)
PI     US 6399335          B1   20020604
AI     US 1999-441108           19991116 (9)
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Riley, Jezia
LREP   Osman, Richard Aron
CLMN   Number of Claims: 23
ECL    Exemplary Claim: 1
DRWN   0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The invention provides methods and compositions for polymerizing a
       particular nucleotide with a polymerase. In general, the method involves
       (a) forming a mixture of a polymerase and a nucleoside triphosphate
       (NTP) comprising α, β and γ phosphates and a
       γ-phosphate phosphoester-linked functional group; and incubating
       the mixture under conditions wherein the polymerase catalyzes cleavage
       of the NTP between the α and β phosphates, liberating a
       pyrophosphate comprising the functional group and polymerizing the
       resultant nucleoside monophosphate, i.e. incorporates the nucleoside
       monophosphate in a nascent polynucleotide. A variety of functional
```

groups compatible with the polymerization reaction are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l2 2 kwic